Literature DB >> 12467977

The Trypanosoma cruzi membrane glycoprotein AGC10 inhibits human lymphocyte activation by a mechanism preceding translation of both, interleukin-2 and its high-affinity receptor subunits.

Felipe Kierszenbaum1, Manuel Fresno, Marcelo B Sztein.   

Abstract

Like living Trypanosoma cruzi, its AGC10 membrane glycoprotein inhibits interleukin-2 (IL-2) secretion and membrane expression of CD25, CD122, and CD132 (the components of the high-affinity IL-2 receptor) by activated human lymphocytes. Since these molecules are required for effective lymphocyte division, we explored the molecular mechanism underlying these alterations. In the presence of AGC10 the cytoplasmic levels of IL-2 protein of CD4(+) and CD8(+) blood lymphocytes stimulated with phorbol myristate acetate (PMA) plus ionomycin were markedly reduced. AGC10 also decreased the intracellular levels of CD25, CD122, and CD132 in CD4(+) and CD8(+) cells stimulated with the T-cell mitogen phytohemagglutinin (PHA). These results indicated that the AGC10-induced alterations preceded IL-2 secretion and transport of IL-2 receptor components to the cell membrane. Supporting this view were the substantially diminished levels of IL-2, CD25, CD122, and CD132 mRNA found in AGC10-containing cultures of PHA-activated lymphocytes. These decreases were not due to increased mRNA instability. Thus, the rates of decay for each of these mRNA species were comparable in the presence or absence of AGC10, suggesting a mechanism involving transcription inhibition. AGC10 targeted an early lymphocyte activation event since inhibition of lymphoproliferation subsided when AGC10 was added to cultures at or after 20 h post-activation. AGC10 also caused large reductions in the mRNA levels of cyclin D2 and cdk4, both critical for progression through G1. These results show for the first time that AGC10-induced inhibition of lymphoproliferation entails curtailed biosynthesis of IL-2 and, IL-2 receptor molecules, and suggest that the effect involves inhibition of gene transcription.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12467977     DOI: 10.1016/s0166-6851(02)00217-7

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  6 in total

1.  Inhibitory effects of Trypanosoma cruzi sialoglycoproteins on CD4+ T cells are associated with increased susceptibility to infection.

Authors:  Marise Pinheiro Nunes; Bárbara Fortes; João Luiz Silva-Filho; Eugênia Terra-Granado; Leonardo Santos; Luciana Conde; Isadora de Araújo Oliveira; Leonardo Freire-de-Lima; Marina Vieira Martins; Ana Acacia Sá Pinheiro; Christina Maeda Takyia; Célio Geraldo Freire-de-Lima; Adriane Regina Todeschini; George Alexandre Dosreis; Alexandre Morrot
Journal:  PLoS One       Date:  2013-10-28       Impact factor: 3.240

Review 2.  The Role of Sialic Acid-Binding Receptors (Siglecs) in the Immunomodulatory Effects of Trypanosoma cruzi Sialoglycoproteins on the Protective Immunity of the Host.

Authors:  Alexandre Morrot
Journal:  Scientifica (Cairo)       Date:  2013-12-22

Review 3.  Evasion and Immuno-Endocrine Regulation in Parasite Infection: Two Sides of the Same Coin in Chagas Disease?

Authors:  Alexandre Morrot; Silvina R Villar; Florencia B González; Ana R Pérez
Journal:  Front Microbiol       Date:  2016-05-23       Impact factor: 5.640

4.  GRAIL and Otubain-1 are Related to T Cell Hyporesponsiveness during Trypanosoma cruzi Infection.

Authors:  Cinthia C Stempin; Jorge D Rojas Marquez; Yamile Ana; Fabio M Cerban
Journal:  PLoS Negl Trop Dis       Date:  2017-01-23

Review 5.  Immune Evasion Strategies of Trypanosoma cruzi.

Authors:  Ana Flávia Nardy; Célio Geraldo Freire-de-Lima; Alexandre Morrot
Journal:  J Immunol Res       Date:  2015-07-09       Impact factor: 4.818

Review 6.  Interactions between Trypanosoma cruzi Secreted Proteins and Host Cell Signaling Pathways.

Authors:  Renata Watanabe Costa; Jose F da Silveira; Diana Bahia
Journal:  Front Microbiol       Date:  2016-03-31       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.